SCHEMBL3555340

SCHEMBL3555340

CCOC(=O)C1CCN(c2ncc(F)cc2C)CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.56
RAB9A P51151 1/20 0.56
ALDH1A1 P00352 9/20 0.55
KDM4E B2RXH2 5/20 0.55
KMT2A Q03164 3/20 0.55
MEN1 O00255 1/20 0.55
LMNA P02545 1/20 0.55
POLB P06746 3/20 0.54
MAPK1 P28482 3/20 0.53
TP53 P04637 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
RECQL P46063 1/20 0.47
LGMN Q99538 1/20 0.47
TSHR P16473 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
ALOX12 P18054 1/20 0.47
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3543466 0.88 LGMN (0.54) MAPTRAB9AALDH1A1KDM4EKMT2A
SCHEMBL3561809 0.88 MAPT (0.58) MAPTRAB9AALDH1A1KDM4EKMT2A
SCHEMBL10278259 0.84 MAPT (0.55) MAPTRAB9AALDH1A1KDM4EKMT2A
SCHEMBL10278139 0.83 KDM4E (0.50) ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL20564967 0.82 PTPN11 (0.53) MAPTRAB9AALDH1A1KDM4EKMT2A
SCHEMBL3436507 0.82 KDM4E (0.51) RAB9AALDH1A1KDM4ELMNAPOLB
SCHEMBL5025161 0.80 MAPT (0.51) MAPTRAB9AALDH1A1KDM4EKMT2A
SCHEMBL3436735 0.80 OPRK1 (0.43) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL30754934 0.79 KMT2A (0.54) MAPTRAB9AALDH1A1KDM4EKMT2A
SCHEMBL326931 0.79 L3MBTL1 (0.58) MAPTALDH1A1POLBTP53TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163746-B2 Azolecarboxamide derivative ASTELLAS PHARMA INC. (JP) 2012-04-24 US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 US disclosed
EP-2009005-A1 AZOLECARBOXAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 MAPT 1330/4885RAB9A 4401/4885ALDH1A1 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.